Expert commentary: SGLT2 inhibition in type 1 diabetes patients
John Wilding has been sitting on the fence about the prospects for SGLT2 inhibitors in type 1 diabetes. Is he swayed by the latest findings? (3:43)
John Wilding has been sitting on the fence about the prospects for SGLT2 inhibitors in type 1 diabetes. Is he swayed by the latest findings? (3:43)
Learn more about the 2020 World Diabetes Day theme.
Version: 0.1257.0